RANBAXY

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 11, 2008, titled "Ranbaxy enters the Chyawanprash Market; Launches its Sugar Free Brand - Chyawan Active". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_11012008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that the ESOPs Allotment Committee of Directors meeting held today i.e. January 10, 2008 has allotted 82,830 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 373153659 Equity Shares of Rs.5 each aggregating Rs.1865768295.

Ranbaxy Laboratories Ltd has informed the Exchange that "Dr. Brain W. Tempest, Chief Mentor and Executive Vice Chairman of the Board of Directors of the Company has retired from the services of the Company effective close of business hours on December 31, 2007 on completion of his term".

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 31, 2007, titled "Ranbaxy receives final approval to manufacture and market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_31122007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 06, 2007, titled "Ranbaxy receives approval to manufacture and market ARV Combination for Children in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_06122007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that "Zenotech Laboratories Limited (Zenotech) has allotted on preferential basis, 54,89,536 Equity Shares of Rs.10 each at a premium of Rs.150 per share for cash (being 16% of the equity share Capital of Zenotech as increased by the above-mentioned preferential issue) to Ranbaxy Laboratories Ltd. on November 23, 2007. Intimation from Zenotech regarding allotment of the aforesaid shares has been received by the Company today, i.e. November 26, 2007".

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated November 21, 2007, titled "Ranbaxy Launches RAN(R)-Tamsulosin Hydrochloride Capsules in Canada". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_21112007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that "Pursuant to Escrow Agreement dated November 5, 2007 entered amongst Ranbaxy Laboratories Limited ("Ranbaxy"),Dr. Jayaram Chigurupati and his associated [Promoters of Zenotech Laboratories Ltd. ("Zenotech") hereinafter referred as the "Promoter"] and the Hongkong and Shanghai Banking Corporation Limited (HSBC) and Share Purchase Agreement dated October 3, 2007, 78,78,906 Equity Shares of Zenotech (being 27.35% of the present equity share capital of Zenotech) have been put under Escrow Arrangement with HSBC by running the transaction throu

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated November 08, 2007, titled "Ranbaxy and Astellas/Boehringer Ingelheim enter into an Agreement to resolve Tamsulosin U.S. Patent Litigation". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_08112007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 30, 2007, titled "Ranbaxy Granted Favorable Decision By Federal Patent court In Germany - On Pfizer's 281 Atorvastatin Patent". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements)<a href=/content/corporate/Ranbaxy_PR_30102007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 29, 2007, titled "Ranbaxy Receives Tentative Approval From US FDA For Valsartan Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements)<a href=/content/corporate/Ranbaxy_PR_29102007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 24, 2007, titled "Ranbaxy launches Osonase Nasal Spray in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_24102007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 22, 2007, titled "Ranbaxy receives approval to market Ran (R)-Lisinopril in Canada". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_221012007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 18, 2007, titled "Ranbaxy's Q3 PAT increases 48%, Stands at Rs.2,074 MN". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_18102007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that the Board of Directors at its meeting held on October 18, 2007 has approved payment of interim dividend of Rs.2.50 per share for the year ending December 31, 2007. Record date for determination of entitlement of the interim dividend has been fixed as November 02, 2007. Interim Dividend will be paid to the eligible shareholders on or before November 14, 2007.

Ranbaxy Laboratories Ltd has informed the Exchange that: "The ESOPs Allotment Committee of Directors meeting held today i.e. October 10, 2007 has allotted 1,14,966 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 373070829 Equity Shares of Rs.5 each aggregating Rs.1865354145".

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 04, 2007, titled "Ranbaxy First To Gain Approval To Manufacture and Market Clarithromycin For Oral Suspension, USP". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_04102007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 03, 2007, titled "Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology to enhance equity stake in Zenotech Laboratories to 45%". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_03102007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 24, 2007, titled "Ranbaxy forays into Liver Cancer Market - Enters into an In-licensing agreement with Sirtex, Australia Ranbaxy to market in India, Bangladesh, Sri Lanka and Nepal". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_24092007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 13, 2007, titled "Canadian Federal Court favours Ranbaxy - Dismisses Pfizer's application on Atorvastatin Patent CA 2,220,455". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_13092007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 10, 2007, titled "Ranbaxy receives WHO pre-qualification for three additional ARVs-Two products introduced for the first time on the WHO list". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_10092007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 22, 2007, titled "Ranbaxy launches Urology Drug Roliflo* OD based on Multiparticulate NDDS Technology". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_22082007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 20, 2007 titled "Ranbaxy receives US FDA approval to manufacture and market Hydrocodone Bitartrate and Acetaminophen Tablets USP". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_200807.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 30, 2007, titled "Ranbaxy Commercialises its First Authorised Generic, ISOPTIN(R)SR, in the US". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_300707.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 26, 2007, titled "Ranbaxy and Gsk Enter into an agreement to settle valacyclovir US Patent Litigation". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_260707.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 19, 2007, titled "Ranbaxy Q2 Global Sales at USD 395 MN, up 25% (Rs.1,624 CR)". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_19072007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding the consolidated Results for the half year ended on 30-JUN-2007 as follows: Net Sales of Rs. 316450 lacs for half year ending on 30-JUN-2007 against Rs. 269700 lacs for the half year ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 39110 lacs for the half year ending on 30-JUN-2007 against Rs. 19250 lacs for the half year ending on 30-JUN-2006.

Ranbaxy Laboratories Ltd has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 161100 lacs for quarter ending on 30-JUN-2007 against Rs. 143390 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 26350 lacs for the quarter ending on 30-JUN-2007 against Rs. 12110 lacs for the quarter ending on 30-JUN-2006.

Ranbaxy Laboratories Ltd has informed the Exchange regarding the standalone Results for the half year ended on 30-JUN-2007 as follows: Net Sales of Rs. 200280 lacs for half year ending on 30-JUN-2007 against Rs. 182925 lacs for the half year ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 40643 lacs for the half year ending on 30-JUN-2007 against Rs. 15007 lacs for the half year ending on 30-JUN-2006.

Ranbaxy Laboratories Ltd has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 101463 lacs for quarter ending on 30-JUN-2007 against Rs. 104373 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 29115 lacs for the quarter ending on 30-JUN-2007 against Rs. 9983 lacs for the quarter ending on 30-JUN-2006.

Ranbaxy Laboratories Ltd has informed the Exchange that: "the Company has decided to close its manufacturing facility located at E-2/E-3, MIDC, Jejuri, Pune-412303 with effect from July 13, 2007 for being unviable".

Ranbaxy Laboratories Ltd has informed the Exchange that the ESOPs Allotment Committee of Directors in its meeting held today i.e. July 12, 2007 has allotted 95,384 Equity Shares on exercise of Stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 372955863 Equity Shares of Rs. 5 each aggregating Rs. 1864779315".

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 10, 2007, titled "Ranbaxy Receives Final US FDA Approval To Manufacture And Market Amlodipine Besylate Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_10072007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated June 25, 2007, titled "Ranbaxy launches Pravastatin Sodium 80 MG Tablets in USA; Ranbaxy to benefit from 180 day exclusivity". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_250607.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated June 22, 2007, titled "Ranbaxy receives tentative approval from US FDA for Tamsulosin Capsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_22062007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated June 20, 2007, titled "Ranbaxy receives tentative approval from US FDA to manufacture and market Amlodipine Besylate Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_20062007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that: "M/s Jupiter BioScience Limited, Secunderabad has made a Preferential Allotment of 31,77,500 Equity Share Warrants of Rs. 147 each to Ranbaxy Laboratories Limited on May 28, 2007".

Ranbaxy Laboratories Ltd has informed the Exchange that: "The Members of the Company at the Annual General Meeting held today i.e. May 31, 2007, inter-alia, unanimously approved: 1) Re-appointment of Mr. Vivek Bharat Ram, Dr. P. S. Joshi and Mr. Vivek Mehra as Directors of the Company liable to retire by rotation. 2) Re-appointment of M/s. Walker, Chandiok & Co. as Auditors of the Company and authorized the Board of Directors to fix their remuneration. 3) Appointment of Mr. Atul Sobti as Whole-time Director of the Company for a period of five years effective January 18, 2007, payment of remune

Ranbaxy Laboratories Ltd has informed the Exchange that: "Mr. Sunil Godhwani was appointed as a Director of the Company in the casual vacancy caused by resignation of Mr. Tejendra Khanna who would have otherwise held office of Director upto the Annual General Meeting (AGM) i.e. May 31, 2007. Accordingly, Mr. Godhwani's term as a Director in the aforesaid casual vacancy ended on the conclusion of the AGM held today i.e. May 31, 2007. Subsequent to the AGM, the Board at its meeting held on May 31, 2007 appointed Mr. Sunil Godhwani as an Additional Director of the Company".

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 29, 2007, titled "Ranbaxy Wins on all Four Atorvastatin Patents in Norway". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_300507.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 28, 2007, titled "Ranbaxy Expands Its Presence in the U.S. Dermatology Market Through the Acquisition of 13 Brands from Bristol Myers Squibb". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR280507.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 21, 2007, titled "Ranbaxy Receives Approval to Market Ran (R) - Pravastatin in Canada". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RanbaxyPR210507.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 18, 2007, titled "Ranbaxy receives Tentative FDA approval for Fexofenadine Hydrochloride Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RanbaxyPR180507.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 08, 2007, titled "Pharmaceutical Major Ranbaxy Laboratories Extends Roots in South Africa with Finalisation of BE-TABS Acquisition". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR070507.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 27, 2007, titled "Ranbaxy Q1 2007 Net Profit rises 79% to Rs 129 Crores; Operating Profit before Tax at Rs 160 Crores, up 100%; Global Sales at Rs 1,564 Crores record growth of 23%; Management ups guidance for full year to 20% sales growth". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_270407.zip target=NEW> For more detai

Ranbaxy Laboratories Ltd has informed the Exchange that "The Board of Directors at its meeting held today i.e. April 27, 2007 has : (1) Elected Mr. Harpal Singh as Non - Executive Chairman of the Board of Directors. He has been a Director on the Board since July, 2000; and (2) Appointed Mr. Sunil Godhwani as a Director of the Company in the casual vacancy caused by the resignation of Mr. Tejendra Khanna. Mr. Godhwani is the CEO & Managing Director of Religare Enterprises Limited and Managing Director of Fortis Financial Services Ltd. He is aged about 46 years with over twenty years of working

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 26, 2007, titled "Ranbaxy Receives Final US FDA Approval to Manufacture and Market Zolpidem Tablets in USA". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR260407.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 25, 2007, titled "Ranbaxy receives US FDA approval to manufacture and market Pravastatin Sodium Tablets in USA - Ranbaxy granted 180 days exclusivity for 80MG Dosage". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/rANBAXY_pr_25042007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that "The ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on April 13, 2007, allotted 81,658 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 372860479 Equity Shares of Rs.5 each aggregating Rs.1864302395".

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 12, 2007, titled "Ranbaxy Receives Approval to Market Cefprozil Tablets and Cefprozil Powder for Oral Suspension in Canada". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR.zip target=NEW> For more details click here.</a>